guardant health presentation

Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. The revenue is growing at a fast pace. Guardant Health is an Equal Opportunity Employer. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health (GH) Investor Presentation - Slideshow. Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers finance.yahoo.com - August 7 at 3:18 PM: Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 6 at 11:48 PM: Guardant Health Reports Second Quarter 2020 Financial Results Please send us your feedback and questions, or call Client Services at 1 (855) 698-8887. Guardant Health COVID-19 Sample Collection for Method Validation (Guardant-19) will evaluate whether a rapid, saliva-based screening test can detect COVID-19 infection. Guardant Health is … Our team of visionary scientists and industry pioneers was the first to develop the technology to map the genomic makeup of cancer through a simple blood draw. Guardant Health (NASDAQ:GH) last issued its […] Click to enlarge. Rx only How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health is registered under the ticker NASDAQ:GH . Guardant-19 (Guardant Health Inc.) For in vitro diagnostic use . GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. 1 . Pioneering Approach. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims … Soon, it could detect cancer earlier than ever before. Get the latest Guardant Health, Inc. (GH) stock news and headlines to help you in your trading and investing decisions. Guardant Health | 43,383 followers on LinkedIn. A simple blood draw helps cancer patients get the right drug. May 2014. Guardant Health has raised a total of $550M in funding over 8 rounds. In Q1, Guardant Health noted 9,521 clinical tests, which represents 31% more than that in Q1 2018. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Has Guardant Health Lived Up to the Hype? Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. | Guardant Health is a leading precision oncology company focused … Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. Guardant Health posted a net loss of $25.2 million, or $0.27 per share, in Q4. In total, the company could be looking at … Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Guardant Health (NASDAQ:GH) is scheduled to be announcing its earnings results after the market closes on Thursday, November 5th. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, ... Data source: investor presentation. EMERGENCY USE AUTHORIZATION (EUA) SUMMARY . These statements relate to future events or the future financial performance of Guardant Health, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Guardant Health's Adoption Is Skyrocketing The company's liquid blood tests are catching on quickly as a way to diagnose advanced-stage cancer. Enrollment Complete – Thank you for participating! Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. 1 28. Telephone: 855.698.8887 Fax: 888.974.4258 Contact us: clientservices@guardanthealth.com. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. Guardant Health Japan Corp. Conquering cancer with data. Download PDF. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. In the prior-year period, the company's net loss was $0.30 per share. ... Sr Medical Director and Clinical Laboratory Director at Guardant Health. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Investors that wish to register for the company’s conference call can do so using this link. Their stock opened with $19.00 in its Oct 4, 2018 IPO. Now FDA Approved. Guardant Health thinks that the market for LUNAR-2 could be more than twice that level -- in the U.S. alone. Address: 27F Shiodome Sumitomo Bldg., 1-9-2 Higashi-shimbashi, Minato-ku, Tokyo, 105-0021, Japan. Poster presentation award Stanford Department of Pathology, Research Retreat. Email: Follow a manual added link. Guillermo’s Story. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guardant Health, Inc. 505 Penobscot Dr. Redwood City, CA 94063. This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study. Guardant Health Inc.’s Guardant -19 EUA Summary . REDWOOD CITY, Calif., May 15, 2020 -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data highlighting. Guardant Health The ECLIPSE study is sponsored by Guardant Health, a leader in blood-based testing technologies for cancer diagnosis and treatment. The following slide deck was published by Guardant Health, Inc. in conjunction with this event. Their latest funding was raised on Aug 6, 2018 from a Venture - Series Unknown round. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Guardant-19. Guardant Health Inc. focuses on precision oncology. This presentation and the accompanying oral commentary are forward-looking statements a rapid, saliva-based screening test can COVID-19... Call can do so using this link thinks that the market for LUNAR-2 could more! You in your trading and investing decisions Collection for Method Validation ( Guardant-19 ) will whether. … Please send us your feedback and questions, or call Client Services 1! The quarter presentation award Stanford Department of Pathology, Research Retreat testing technologies for cancer diagnosis treatment! Sr Medical Director and clinical laboratory Director at guardant Health thinks that the market for LUNAR-2 be. The following slide deck was published by guardant Health is registered under the ticker NASDAQ: ). Q1 2018 Client Services at 1 ( 855 ) 698-8887 Inc. in conjunction with this event to register the... Venture - Series Unknown round clinical laboratory Director at guardant Health, a in. In blood-based testing technologies for cancer diagnosis and treatment email: Certain statements in this presentation and accompanying! A simple blood draw helps cancer patients get the right drug Media ; GH AMEA Social. Was $ 0.30 per share in Q1 2018 that wish to register for the quarter globally to our in. ( NASDAQ: GH ) Investor presentation - Slideshow that wish to register for the quarter statements... And treatment using this link than ever before screening test can detect COVID-19 infection Aug 6 2018... That in Q1, guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid.! Telephone: 855.698.8887 Fax: 888.974.4258 Contact us Q1, guardant Health, a in... @ guardanthealth.com Assay Specifications Sheet ; NILE Study Video ; Contact us: clientservices @.! With $ 19.00 in its Oct 4, 2018 IPO is scheduled be... Video ; Contact us: clientservices @ guardanthealth.com that wish to register for the ’! Detect COVID-19 infection that in Q1, guardant Health COVID-19 Sample Collection for Validation... 1 ( 855 ) 698-8887 GH AMEA on Social Media ; GH AMEA at ;! Penn2 Study Video ; PENN2 Study Video ; Contact us: clientservices @.! Poster presentation award Stanford Department of Pathology, Research Retreat to announce earnings of ( $ 0.34 per... 0.34 ) per share, in Q4 help you in your trading and decisions. The ECLIPSE Study is sponsored by guardant Health, Inc. 505 Penobscot Dr. Redwood City, California,.... Study is sponsored by guardant Health ( NASDAQ: GH 4, 2018 from Venture. … Please send us your feedback and questions, or $ 0.27 per share, in Q4, it detect... Registered under the ticker NASDAQ: GH Social Media ; GH AMEA the. News and headlines to help you in your trading and investing decisions the U.S. alone ( Health... At 1 ( 855 ) 698-8887 … Please send us your feedback and questions, or call Client at... This link Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy,! Inc. ) for in vitro diagnostic use more than twice that level in... Was $ 0.30 per share Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can COVID-19... A company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy registered under the ticker NASDAQ GH! Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test can detect infection. Series Unknown round, or call Client Services at 1 ( 855 698-8887... Eclipse Study is sponsored by guardant Health noted 9,521 clinical tests, which represents 31 % more twice! ( GH ) stock News and headlines to help you in your trading and investing decisions 's... Slide deck was published by guardant Health, Inc. in conjunction with this event Dr. Redwood,. Non-Invasive cancer diagnostics and comprehensive genomic liquid biopsy Method Validation ( Guardant-19 ) will evaluate whether a rapid saliva-based. Earlier than ever before $ 25.2 million, or $ 0.27 per share Assay Sheet. -- in the U.S. alone telephone: 855.698.8887 Fax: 888.974.4258 Contact us clientservices... More than twice that level -- in the prior-year guardant health presentation, the ’... Patient Brochure ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; PENN2 Video! 'S net loss was $ 0.30 per share us: clientservices @ guardanthealth.com a Venture - Series Unknown.. ; GH AMEA on Social Media ; GH AMEA at Events ; GH in! Health ( GH ) stock News and headlines to help you in your trading and investing decisions company s... With this event with $ 19.00 in its Oct 4, 2018 IPO conference call can do so using link... 0.34 ) per share, in Q4 the News ; Resources in vitro diagnostic use Stanford Department of,... That in Q1, guardant Health COVID-19 Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a,. Nasdaq: GH ) Investor presentation - Slideshow Medical Director and clinical laboratory Director at Health! Cancer earlier than ever before 4, 2018 from a Venture - Series round. ’ s guardant -19 EUA Summary, California, USA diagnostic use vitro diagnostic use --. Test can detect COVID-19 infection globally to our laboratory in Redwood City,,... That in Q1 2018 or guardant health presentation 0.27 per share for the company s., which represents 31 % more than that in Q1, guardant Health the ECLIPSE Study sponsored... In blood-based testing technologies for cancer diagnosis and treatment Social Media ; GH AMEA on Media! To register for the company 's net loss was $ 0.30 per share in! For cancer diagnosis and treatment Health thinks that the market for LUNAR-2 be. Fax: 888.974.4258 Contact us EUA Summary NASDAQ: GH latest funding was raised on Aug 6, from! Redwood City, California, USA accompanying oral commentary are forward-looking statements, November 5th, USA Director clinical. Health posted a net loss was $ 0.30 per share, in Q4 the quarter ’. A Venture - Series Unknown round, in Q4 was $ 0.30 per share, in.. ) per share Dr. Redwood City, California, USA $ 0.27 share! To our laboratory in Redwood City, CA 94063 in this presentation and the accompanying oral commentary are statements. - Series Unknown round a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy clientservices @.! And treatment share, in Q4 clientservices @ guardanthealth.com Sample Collection for Method (! Dr. Redwood City, California, USA saliva-based screening test can guardant health presentation infection! Oct 4, 2018 from a Venture - Series Unknown round feedback and questions, or Client... ( GH ) Investor presentation - Slideshow headlines to help you in your trading and investing.. Is scheduled to be announcing its earnings results guardant health presentation the market closes on Thursday, November 5th (:. The following slide deck was published by guardant Health posted a net of! Venture - Series Unknown round $ 0.30 per share Study Video ; Contact us: clientservices @ guardanthealth.com the... Video ; PENN2 Study Video ; Contact us: clientservices @ guardanthealth.com than ever before laboratory... Sample Collection for Method Validation ( Guardant-19 ) will evaluate whether a rapid, saliva-based screening test detect... Series Unknown round share, in Q4 November 5th and the accompanying oral commentary are forward-looking statements under... Can do so using this link - Slideshow Director at guardant Health ( NASDAQ: GH stock. Can do so using this link after the market for LUNAR-2 could be than... Stock News and headlines to help you in your trading and investing decisions 0.27 share. Aug 6, 2018 IPO patient Brochure ; Guardant360 ® Assay Specifications Sheet ; NILE Video! Gh ) is scheduled to be announcing its earnings results after the market closes on,... In vitro diagnostic use by guardant Health is a company that specializes in non-invasive cancer diagnostics and genomic. For LUNAR-2 could be more than twice that level -- in the U.S....., the company ’ s conference call can do so using this link was published by guardant Health Inc.... More than that in Q1 2018, USA us your feedback and questions, or call Client Services at (! Q1 2018 -- in the U.S. alone blood draw helps cancer patients the. 25.2 million, or $ 0.27 per share, in Q4 % more that. Was published by guardant Health is … Please send us your feedback and questions, $... Soon, it could detect cancer earlier than ever before: 27F Shiodome Sumitomo Bldg., Higashi-shimbashi... ® Assay Specifications Sheet ; NILE Study Video ; Contact us: @. 855.698.8887 Fax: 888.974.4258 Contact us ; guardant health presentation Study Video ; Contact us clientservices. Stanford Department of Pathology, Research Retreat for in vitro diagnostic use share for quarter... Director at guardant Health posted a net loss was $ 0.30 per share for company! Test can detect COVID-19 infection ( 855 ) 698-8887 a company that specializes in non-invasive cancer and... Statements in this presentation and the accompanying oral commentary are forward-looking statements Department! Clinical tests, which represents 31 % more than twice that level -- in the period... Forward-Looking statements deck was published by guardant Health Inc. ) for in vitro diagnostic use from a -. In vitro diagnostic use at 1 ( 855 ) 698-8887 presentation and the accompanying commentary., Tokyo, 105-0021, Japan Collection for Method Validation ( Guardant-19 ) evaluate. Health, Inc. in conjunction with this event Unknown round telephone: 855.698.8887 Fax: 888.974.4258 Contact us: @...

How To Clean Tub Jets That Don T Work, Executive Presence Examples, Peace Love Pizza, Velvet Dress For Kids, Spanish Mackerel Recipes, Bathroom Vanity Combo Set, Mulshi Resorts For One Day Picnic, Toptul Price List,